Achieve Life Sciences Welcomes Dr. Rubinstein to Lead Medical Affairs
Achieve Life Sciences Enhances Leadership Team
Achieve Life Sciences, Inc. (NASDAQ: ACHV), a pharmaceutical company dedicated to the development of cytisinicline for smoking cessation and nicotine dependence, has announced a significant enhancement to its leadership with the appointment of Dr. Mark L. Rubinstein as the new Head of Medical Affairs. Dr. Rubinstein arrives with over twenty years of clinical and research experience, making him a strong addition to this innovative firm.
Dr. Rubinstein's Expertise and Vision
Dr. Rubinstein's extensive background in clinical medicine and nicotine cessation aligns perfectly with Achieve Life Sciences' mission. His career reflects a robust commitment to improving public health through preventative medicine and effective interventions targeting nicotine dependence. This strategic appointment comes at a critical juncture as the company advances its mission in smoking and vaping cessation.
Insights from Leadership
Rick Stewart, the CEO of Achieve Life Sciences, expressed excitement regarding Dr. Rubinstein’s appointment, stating, "We are thrilled to welcome Mark to our team at this pivotal time. His vast experience in smoking and vaping cessation, coupled with his leadership in medical affairs, will be instrumental in shaping our future initiatives aimed at nicotine dependence reduction.”
Dr. Rubinstein's Previous Contributions
Before joining Achieve, Dr. Rubinstein led the Medical Affairs at Blip, focusing on strategies to assist smokers and vapers in quitting through FDA-approved treatments and support tools. His previous role as Vice President of Global Scientific Affairs at Juul Labs further solidified his reputation in nicotine product intervention strategies, particularly aimed at youth prevention initiatives.
Contributions to Nicotine Cessation Research
Dr. Rubinstein has made significant contributions to nicotine addiction research. He is a Professor Emeritus of Pediatrics at the University of California, San Francisco. His research initiatives have received funding from renowned organizations, including the NIH, and have produced numerous impactful studies published in prestigious journals. This wealth of experience positions him as a leading advocate in nicotine addiction and smoking cessation.
Media Recognition
As a recognized thought leader, Dr. Rubinstein has been featured in a variety of media, such as ABC Nightly News, NPR, and major newspapers like The New York Times. His expertise and commitment to improving health outcomes through digital media resonate with Achieve Life Sciences' dynamic approach to tackling nicotine dependency.
About Cytisinicline and Achieve Life Sciences
Achieve Life Sciences is focused on combatting the global smoking health crisis through cytisinicline development. With approximately 29 million adults in the U.S. smoking combustible cigarettes and millions more using e-cigarettes, the need for effective treatments remains critical. Tobacco use causes over eight million deaths globally each year, underlining the urgency of this potential therapeutic solution.
Addressing Nicotine Addiction
Cytisinicline represents an exciting plant-based alkaloid showing promise in treating nicotine addiction. Its mechanism involves binding to nicotinic receptors in the brain, decreasing withdrawal symptoms, and mitigating the rewarding effects associated with nicotine consumption. Though currently an investigational product, it has the potential to become one of the first new therapies for nicotine dependence in nearly two decades.
Investor Relations and Media Contacts
For any inquiries, please reach out to:
Investor Relations Contact
Rich Cockrell
Email: achv@cg.capital
Phone: (404) 736-3838
Media Contact
Glenn Silver
Email: Glenn.Silver@Finnpartners.com
Phone: (646) 871-8485
Frequently Asked Questions
What is Achieve Life Sciences focused on?
Achieve Life Sciences focuses on developing cytisinicline as a solution for smoking cessation and nicotine dependence.
Who has been appointed as the Head of Medical Affairs?
Dr. Mark L. Rubinstein has been appointed as the new Head of Medical Affairs at Achieve Life Sciences.
What experience does Dr. Rubinstein bring to Achieve Life Sciences?
Dr. Rubinstein brings over two decades of experience in clinical medicine and a strong focus on nicotine cessation and prevention strategies.
What is cytisinicline, and how does it help?
Cytisinicline is a plant-based alkaloid believed to assist individuals in overcoming nicotine addiction by interacting with brain receptors and reducing withdrawal symptoms.
Why is this appointment significant for Achieve Life Sciences?
Dr. Rubinstein’s appointment is significant as it enhances Achieve’s leadership capabilities at a crucial moment in the company’s pursuit of regulatory approval and market entry for cytisinicline.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.